Celcuity

Celcuity CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Celcuity (CELC) as of Nov 11, 2026 is -0.16 %. In the previous year, CapEx to Operating Cash Flow Ratio was -0.30 % — a change of -45.74% (higher).

CapEx/OCF

-0.16 %

YoY

-45.74%

Last updated:

CapEx to Operating Cash Flow Ratio of Celcuity is 2025 -0.16 % . CapEx to Operating Cash Flow Ratio of Celcuity was 2024 -0.30 % . It decreases by -45.74% higher compared to the previous year.

The Celcuity CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-10.36 USD
Jan 1, 2019
-6.34 USD
Jan 1, 2020
-1.25 USD
Jan 1, 2021
-0.40 USD
Jan 1, 2022
-0.44 USD
Jan 1, 2023
-0.18 USD
Jan 1, 2024
-0.30 USD
Jan 1, 2025
-0.16 USD
The Celcuity CapEx/OCF history
YEARCapEx/OCFYoY
-0.16 %-45.74%
-0.30 %+64.99%
-0.18 %-58.85%
-0.44 %+9.36%
-0.40 %-67.76%
-1.25 %-80.27%
-6.34 %-38.83%
-10.36 %+113.76%
-4.85 %+242.29%
-1.42 %-64.52%
-3.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

CapEx to Operating Cash Flow Ratio of Celcuity is -0.16 % in 2025.

CapEx to Operating Cash Flow Ratio of Celcuity changed from -0.30 % to -0.16 %, representing a -45.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Celcuity since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Celcuity with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Celcuity

All Key Metrics — Celcuity